Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 22, 2015 11:59 PM ET

Biotechnology

Company Overview of Hyperion Therapeutics, Inc.

Company Overview

Hyperion Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat orphan diseases in the United states, Canada, and internationally. The company offers RAVICTI used as a nitrogen-binding agent for chronic management of urea cycle disorder (UCD) in adult and pediatric patients; and BUPHENYL and AMMONAPS therapy for treatment of three UCD subtypes. It is also developing glycerol phenylbutyrate, an active pharmaceutical ingredient in RAVICTI to treat hepatic encephalopathy. The company was founded in 2006 and is headquartered in Brisbane, California.

2000 Sierra Point Parkway

Suite 400

Brisbane, CA 94005

United States

Founded in 2006

80 Employees

Phone:

650-745-7802

Fax:

650-871-7029

Key Executives for Hyperion Therapeutics, Inc.

Chief Executive Officer, President and Director
Age: 53
Chief Financial Officer and Principal Accounting Officer
Age: 52
Chief Commercial Officer and Senior Vice President
Age: 41
Chief Legal Officer, Senior Vice President of Government Affairs and Secretary
Age: 39
Chief Medical Officer
Age: 68
Compensation as of Fiscal Year 2014.

Hyperion Therapeutics, Inc. Key Developments

Hyperion Therapeutics, Inc.(NasdaqGM:HPTX) dropped from NASDAQ Biotechnology Index

Hyperion Therapeutics, Inc. will be removed from NASDAQ Biotech Index.

Hyperion Therapeutics, Inc. Announces Amendments to Certificate of Incorporation

Hyperion Therapeutics, Inc. announced amended and restated certificate of incorporation. Article 1: Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2. Other Offices. The corporation shall also have and maintain an office or principal place of business at such place as may be fixed by the Board of Directors, and may also have offices at such other places, both within and without the State of Delaware, as the Board of Directors may from time to time determine or the business of the corporation may require. ARTICLE II: Section 3. Corporate Seal. The Board of Directors may adopt a corporate seal. The corporate seal shall consist of a die bearing the name of the corporation and the inscription, Corporate Seal-Delaware. ARTICLE III: Place of Meetings. Meetings of the stockholders of the corporation may be held at such place, either within or without the State of Delaware, as may be determined from time to time by the Board of Directors. The Board of Directors may, in its sole discretion, determine that the meeting shall not be held at any place, but may instead be held solely by means of remote communication as provided under the Delaware General Corporation Law (DGCL).

Hyperion Therapeutics, Inc.(NasdaqGS:HPTX) dropped from NASDAQ Composite Index

Hyperion Therapeutics, Inc. will be removed from Nasdaq Composite Index.

Similar Private Companies By Industry

Company Name Region
Abiomed R&D, Inc. United States
CellExSys, Inc. United States
Sustained Release, Inc. United States
Trellis Bioscience, Inc. United States
Alvos Therapeutics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
March 30, 2015
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Hyperion Therapeutics, Inc., please visit www.hyperiontx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.